HDFC Pharma and Healthcare Fund Regular IDCW
NAV ₹22.646 on 13 November 2026
AMFI name: HDFC Pharma and Healthcare Fund - IDCW Option · Scheme code 152083
IDCW option: returns are NAV changes and leave out payouts, so they understate what investors received. Risk ratios are not shown for payout options.
Returns
To 13 November 2026. Up to 1 year: total change. 3 and 5 years: compound return a year.
| Period | This fund | NIFTY HEALTHCARE INDEX TRI | Category median |
|---|---|---|---|
| 1M | +10.33% | +8.67% | +5.63% |
| 6M | +17.73% | +12.84% | +6.99% |
| 1Y | +30.14% | +38.92% | +2.83% |
| 3Y | +29.74% | +28.05% | +13.18% |
| 5Y | - | - | +10.85% |
Benchmark: NIFTY HEALTHCARE INDEX TRI (total return index), measured over the same dates. The scheme document names BSE Healthcare Index (TRI), which we do not hold, so this is the closest NSE index.
Category median: the middle return among Regular plans (Growth option) in AMFI's “Equity Scheme - Sectoral/ Thematic” category, up to 174 funds with clean data. Ranks are under “Rank among peers”.
Rank among peers
Regular plans, Growth option, in AMFI's “Equity Scheme - Sectoral/ Thematic” category. Each rank counts only the peers that have that figure.
| Rank | Scheme Name | 3Y Return | 1Y Return | Sharpe | Direct TER | AUM |
|---|---|---|---|---|---|---|
| #1 | Nippon India Mutual Fund | +46.52% | +60.64% | 1.07 | 1.06% | ₹1,100 Cr |
| #2 | HDFC Mutual Fund | +33.64% | +20.34% | 1.07 | 0.89% | ₹11,128 Cr |
| #3 | HDFC Mutual Fund | +31.28% | +31.60% | 1.76 | 1.03% | ₹3,128 Cr |
| #4 | SBI Mutual Fund | +25.42% | +26.07% | 1.47 | 0.76% | ₹5,565 Cr |
| #5 | HDFC Mutual Fund | +24.77% | +10.10% | 1.09 | 1.10% | ₹1,997 Cr |
| #6 | Mirae Asset Mutual Fund | +24.42% | +27.89% | 1.28 | - | ₹3,458 Cr |
| #7 | UTI Mutual Fund | +23.89% | +22.00% | 1.31 | 1.35% | ₹1,399 Cr |
| #8 | ICICI Prudential Mutual Fund | +22.73% | +10.29% | 0.95 | 2.08% | ₹3,926 Cr |
| #- | HDFC Pharma and Healthcare FundCurrent Fund HDFC Mutual Fund | +29.74% | +30.14% | - | 1.03% | ₹3,128 Cr |
Costs and fund facts
- Expense ratio (stated maximum)
- Direct 1.03% · Regular 2.11%
- Exit load
- In respect of each purchase/switch-in of units, an Exit load of 1% is payable if units are redeemed /switched-out within 30 days from the date of allotment. No Exit Load is payable if units are redeemed / switched out after 30 days from the date of allotment.
- Fund size (all plans)
- ₹3,128 CrAverage, quarter to September 2026
- Benchmark
- BSE Healthcare Index (TRI)Compared here with NIFTY HEALTHCARE INDEX TRI
- Allotment date
- 4 October 2023Scheme document
- Type
- An open-ended equity scheme investing in Pharma and healthcare sector
- AMFI scheme code
- 152083
Fund managers (3)
- Nikhil Mathur
- Gopal Agrawal
- Bhagyesh Kagalkar
How each manager has done since taking over: fund manager scorecard.
Investment objective
To provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies. There is no assurance that the investment objective of the Scheme will be achieved.
From the scheme summary document filed with AMFI.
SIP calculator
A monthly SIP replayed on this fund's actual daily NAVs: what it would be worth today.
IDCW option: values use the NAV only and leave out the payouts, so they understate what an investor received. The Growth option of this fund shows the full return.
About this fund
HDFC Pharma and Healthcare Fund Regular IDCW is a mutual fund scheme from HDFC Mutual Fund, listed by AMFI under “Equity Scheme - Sectoral/ Thematic”. This page covers the Regular plan with the IDCW option. Its NAV was ₹22.646 on 13 November 2026. Its NAV changed by 30.14% over 1 year and 29.74% a year over 3 years. These figures leave out IDCW payouts, so they understate what investors received. Its benchmark, NIFTY HEALTHCARE INDEX TRI, returned 28.05% a year over 3 years. The fund house rates its risk as “Very High Risk” on the SEBI riskometer. Its average assets under management were ₹3,128 Cr across all plans for the quarter ending September 2026, as reported to AMFI. Its scheme summary document states a maximum expense ratio (TER) of 2.11% a year for the Regular plan. Managed by Nikhil Mathur, Gopal Agrawal and Bhagyesh Kagalkar. Its scheme summary document gives the allotment date as 4 October 2023.
Figures are calculated from AMFI NAVs and index data, not taken from fund factsheets. Methodology. Past performance is not a guide to future returns.
Plans and options of this fund (4)
| Plan | Option | ISIN | AMFI code | NAV |
|---|---|---|---|---|
| Direct | Growth | INF179KC1HO1 | - | ₹23.4913 Nov 2026 |
| Direct | IDCW | INF179KC1HQ6 | - | - |
| Regular | Growth | INF179KC1HL7 | - | ₹22.6513 Nov 2026 |
| Regular | IDCW | INF179KC1HN3 | - | - |